MedTrace Logo

Bone Marrow Transplantation Plus Biological Therapy in Treating Patients With Chronic Myeloid Leukemia

NCT00011934 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2014-04-17

No results posted yet for this study

Summary

RATIONALE: Biological therapy may increase the number of immune cells found in bone marrow and may help a person's immune system recover from the side effects of the chemotherapy used in treating chronic myeloid leukemia. Bone marrow transplantation may be able to replace immune cells that were destroyed by chemotherapy.

PURPOSE: Phase II trial to study the effectiveness of bone marrow transplantation, chemotherapy, and biological therapy in treating patients who have chronic myeloid leukemia.

Conditions

Interventions

BIOLOGICAL

recombinant interferon alfa

BIOLOGICAL

sargramostim

PROCEDURE

autologous bone marrow transplantation

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    lead OTHER

Principal Investigators

  • B. Douglas Smith, MD · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Study Design

Purpose
TREATMENT

Eligibility

Min Age
12 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1998-05-31
Primary Completion
2002-08-31
Completion
2002-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00011934 on ClinicalTrials.gov